Selank Benefits: What Small Human Studies Show—and What They Cannot Prove

Selank is unusual among peptides marketed for “calm focus.” It is not supported only by rodent behaviour or forum anecdotes: PubMed indexes several small clinical reports in people with anxiety-related disorders. That makes the evidence more substantial than a purely preclinical story—but much thinner than the confident claims often built around it.

Two commonly cited Russian-language studies compared Selank with benzodiazepines in groups of 60 or 62 patients. Their abstracts reported anxiety improvements, and one described mild nootropic effects. A later 70-patient study examined Selank added to phenazepam. Yet these reports are small, mostly accessible to international readers only through English abstracts, and do not amount to large, independently replicated, placebo-controlled evidence for anxiety treatment, cognition, sleep, “brain optimisation” or everyday stress.[1–3]

The defensible summary is: Selank has limited human comparator evidence suggesting an anxiolytic signal in selected psychiatric populations, plus laboratory research on GABA binding and enkephalin degradation. The public evidence does not establish broad cognitive, mood, sleep or stress-resilience benefits, and it does not provide a complete modern safety profile.

Selank evidence at a glance

What is Selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, often written TKPRPGP. It was derived from the immunomodulatory peptide tuftsin by adding a Pro-Gly-Pro sequence. The short sequence is the starting point for its biological research, not proof of a clinical outcome.[4,5]

Naming needs care. “Selank” and “Selank acetate” may appear in supplier catalogues, while FDA’s current compounding safety page refers specifically to Selank acetate (TP-7). A common name alone does not tell a buyer the exact salt form, counter-ion level, molecular-mass basis or whether a reference standard matches the supplied material.[6]

Selank is also easily confused in search results with Silexan, a lavender-oil preparation with a separate clinical literature. Silexan trials are not Selank trials. A one-letter search error can import hundreds of unrelated participants and a completely different mechanism into an article.

1. What the 62-patient study reported

A 2008 Russian-language report enrolled 62 patients described as having generalised anxiety disorder or neurasthenia. Thirty received Selank and 32 received medazepam. Researchers assessed patients with Hamilton, Zung and Clinical Global Impression scales and also measured serum enkephalin-related variables.[1]

The English abstract states that the groups showed similar anxiolytic effects and that the Selank group also showed antiasthenic and psychostimulant effects. It further reports changes in the measured half-life of leu-enkephalin during treatment, particularly among patients with generalised anxiety disorder.[1]

That is a human comparative signal. It is not the same as a modern confirmatory trial. From the abstract alone, an international reader cannot fully audit allocation concealment, blinding, prespecified primary outcome, missing-data handling, adverse-event collection, protocol registration or the complete numeric results. Medazepam is an active comparator, not a placebo, so the abstract does not independently estimate how much of the observed change exceeded expectancy, time or clinical attention.

The right wording is “a small comparative study reported similar improvement,” not “Selank was proved equal to a benzodiazepine.” Demonstrating equivalence requires a prespecified equivalence or non-inferiority design and margin; the abstract does not establish that standard.

2. What the 60-patient phenazepam comparison adds

A 2014 report compared Selank with phenazepam in 60 people with phobic-anxiety, generalised-anxiety or somatoform diagnoses. Its English abstract describes pronounced anxiolytic and mild nootropic effects, a reported effect lasting for a week after the final administration, and improved quality of life.[2]

Again, those are encouraging results from a clinical population. But the abstract does not provide the detail required to turn them into a universal effect size or safety conclusion. Multiple diagnoses were grouped together. The report was small, and the accessible abstract does not describe a placebo arm or provide a full statistical table for each claim.

“Mild nootropic effect” is particularly easy to overextend. It does not demonstrate enhanced memory, attention, learning speed or executive function in healthy students, professionals or older adults. A secondary observation in people receiving treatment for anxiety is not a validated cognitive-enhancement indication.

3. What the combination study can—and cannot—answer

A later study compared phenazepam alone in 30 patients with Selank plus phenazepam in 40 patients. It used clinical scales, a Stroop test, verbal fluency testing, a tolerability scale and quality-of-life measures. The abstract reported earlier improvement on one scale and fewer unwanted benzodiazepine effects in the combination group.[3]

This design asks whether adding Selank changes a phenazepam treatment course. It cannot isolate Selank’s standalone effect as cleanly as a Selank-versus-placebo trial. Nor does it establish that Selank prevents benzodiazepine adverse effects in routine care.

The study is useful because it shows the research programme looked beyond one symptom score. It remains hypothesis-supporting evidence, not confirmation of a broad “focus without anxiety” promise.

4. Does Selank improve memory, focus or learning?

Online descriptions often move from “mild nootropic effect” to a much larger list: sharper memory, better concentration, faster learning, motivation and mental energy. The human reports above do not collectively demonstrate that package.

To establish cognitive enhancement, a study would need a clearly defined population, placebo control, prespecified cognitive outcomes, practice-effect management, adequate sample size and replication. Testing cognition in an anxiety-treatment study can generate a useful signal, but anxiety relief itself may change test performance. The design has to distinguish direct cognitive enhancement from improved task engagement or reduced distress.

The current evidence therefore supports saying that cognition-related observations have been reported. It does not support marketing Selank as a proven nootropic for healthy people.

5. What laboratory studies suggest about GABA

GABA is the brain’s major inhibitory neurotransmitter, and benzodiazepines influence GABA-A receptor signalling. This makes GABA-related laboratory findings attractive when explaining an anxiolytic peptide.

A 2018 paper examined Selank in radioligand-binding experiments and reported concentration-dependent modulation of labelled GABA binding. The authors proposed that allosteric modulation of GABA receptors could contribute to the anti-anxiety profile.[5]

The phrase “could contribute” matters. A membrane-binding experiment is not a human receptor-occupancy study, and a proposed allosteric effect does not tell us the clinically effective exposure, duration or benefit-risk balance. It also does not make Selank “a natural benzodiazepine” or prove that it shares none of their risks.

Mechanistic research helps formulate testable explanations. It does not replace controlled outcomes.

6. What the enkephalin research means

Enkephalins are endogenous opioid peptides that are broken down by several enzymes. Earlier laboratory work reported that Selank inhibited enzymatic hydrolysis of plasma enkephalin under in-vitro conditions. The 2008 patient study also measured serum enkephalin-related variables and reported correlations with clinical features.[1,4]

These observations provide another biological hypothesis. They do not establish that enzyme inhibition is the main human mechanism, that blood measurements represent brain activity, or that a change in an intermediate marker produces meaningful long-term benefit.

This is a useful evidence hierarchy:

• enzyme inhibition in a laboratory is a biochemical finding;
• a blood-marker correlation is an association;
• symptom change in a small comparative study is a clinical signal;
• replicated placebo-controlled improvement is confirmatory evidence.

Selank research has pieces in the first three levels. The fourth remains limited in the accessible literature.

7. What is known about mood, sleep and everyday stress?

Anxiety, depression, sleep and perceived stress overlap in real life, which encourages one outcome to be marketed as evidence for all four. The cited clinical reports enrolled people with defined psychiatric diagnoses; they were not workplace-stress trials, insomnia trials or major-depression programmes.[1–3]

The studies therefore do not establish that Selank:

• improves sleep quality or sleep duration;
• treats depression;
• prevents panic attacks;
• reduces ordinary work stress in healthy people;
• enhances social confidence or motivation;
• produces durable emotional resilience after long-term use.

Those may be research questions. They are not conclusions supplied by the current studies.

8. How strong is the safety evidence?

Small clinical reports can identify common short-term tolerability problems, but they are poorly suited to detect rare events, subgroup risks, long-term effects or problems caused by variable material quality. A few dozen participants do not make a comprehensive safety database.

FDA’s compounding safety page lists Selank acetate (TP-7) among substances whose nominations were withdrawn after appearing in category 2. FDA states that compounded drugs containing Selank acetate may pose immunogenicity risks for certain routes because of possible aggregation and peptide-related impurities, and that it lacks important information about safety issues raised by Selank acetate administered to humans.[6]

This is not the same as FDA proving that every Selank material is harmful. It does mean that “no side effects” is not a defensible conclusion. Sequence, form, synthesis impurities, aggregation, formulation and route all affect the safety question.

It is also important not to describe the small published reports as FDA approval. A PubMed-indexed clinical paper and an FDA compounding category are different regulatory facts. Selank is not a component of an FDA-approved drug identified in the sources reviewed for this article.

9. Why supplier material is not automatically clinical material

Even if a clinical paper reports a benefit, a B2B research product is not automatically equivalent to the studied material. Equivalence would require evidence connecting identity, sequence, chemical form, content, impurities, formulation, packaging and storage to the clinical preparation.

For a Selank research-material enquiry, a buyer should define:

• exact amino-acid sequence and terminal form;
• free base, acetate or another stated form;
• molecular formula and expected molecular mass;
• counter-ion and mass basis where relevant;
• stated peptide amount per vial and the basis of that claim;
• batch identifier and document traceability;
• identity method and acceptance criteria;
• chromatographic purity method and result;
• quantitative assay or peptide-content information, where available;
• impurity, residual-solvent, water and counter-ion scope;
• storage and shipment conditions for the quoted material.

A peptide COA should be read by method and measured attribute. HPLC area purity does not by itself prove sequence identity, vial content, absence of aggregates, sterility, safety or an anxiolytic effect.

Under MY PEPTIDE Wholesale Terms, each kit contains 10 vials of the same product and the standard MOQ is one kit per peptide. Different products may be combined as complete kits in one order; five vials of A and five of B do not form one kit. Quotations depend on product, per-vial specification and quantity.

FAQ

What benefits of Selank have been studied in humans?

Small comparative studies have investigated anxiety symptoms in patients with generalised-anxiety, phobic-anxiety, somatoform or neurasthenia diagnoses. Their abstracts reported improvement, but they do not provide large, replicated placebo-controlled confirmation.[1–3]

Is Selank a proven nootropic?

No. Cognition-related observations were reported in small clinical studies, but controlled evidence has not established broad memory, focus or learning benefits in healthy people.

Does Selank work through GABA receptors?

Laboratory binding research suggests possible allosteric modulation of GABA-receptor binding. That is a proposed mechanism, not proof of the clinical mechanism in humans.[5]

Is Selank the same as Silexan?

No. Selank is a seven-amino-acid peptide. Silexan is a lavender-oil preparation with a separate evidence base.

Is Selank FDA-approved?

The sources reviewed here do not identify Selank as a component of an FDA-approved drug. FDA’s compounding safety page raises unresolved impurity, aggregation, immunogenicity and human-safety questions for Selank acetate.[6]

Does a high-purity COA prove the same benefit as a clinical study?

No. A purity result describes one analytical attribute of a particular sample. It does not establish equivalence to clinical material or prove safety and efficacy.

Bottom line

Selank should not be described as a peptide with “no human evidence.” Several small human comparative reports exist, and that is worth acknowledging. The opposite claim—“clinically proven for anxiety, cognition, sleep and stress”—also goes beyond the evidence.

The most accurate position sits between those extremes: early patient studies reported an anxiolytic signal; mechanistic experiments offer GABA- and enkephalin-related hypotheses; modern confirmatory evidence, broad healthy-person outcomes and a comprehensive safety record remain limited.

For Selank form, per-vial specifications, kit quantities and batch-document availability, contact service@wholesalepeptide.xyz.

References

1. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38–48. PubMed
2. Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17–22. PubMed
3. Medvedev VE, et al. Optimization of the treatment of anxiety disorders with Selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33–40. doi:10.17116/jnevro20151156133-40
4. Kost NV, Sokolov OIu, Gabaeva MV, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001. PubMed
5. Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein & Peptide Letters. 2018;25(10):914–923. doi:10.2174/0929866525666180925144642
6. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current page reviewed 17 September 2026. FDA